Xenical Switch Proposal Will Face Advisory Committee Review In January
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's Rx-to-OTC switch application for a 60 mg dose of orlistat (Xenical) will be reviewed during a joint meeting of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees Jan. 23, according to the agency
You may also be interested in...
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical's long-term prospect for switch appears promising, but its chances of being recommended for OTC sale by an upcoming advisory panel are slim, some switch experts say
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical's long-term prospect for switch appears promising, but its chances of being recommended for OTC sale by an upcoming advisory panel are slim, some switch experts say
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical's long-term prospect for switch appears promising, but its chances of being recommended for OTC sale by an upcoming advisory panel are slim, some switch experts say